2018
DOI: 10.1007/s40292-017-0244-x
|View full text |Cite
|
Sign up to set email alerts
|

Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 19 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?